Physician profile
Stephen B Lillard
NPI 1285625749
$1,892.37
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $317 · 2021: $421 · 2022: $41.67 · 2023: $18.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $503.16 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.05 | 2019-2021 | |
| Pulmonx Corporation | $157.85 | 2019-2020 | |
| Mylan Specialty L.P. | $124.72 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $75.76 | 2019-2021 | |
| Genentech USA, INC. | $57.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $51.88 | 2019 | |
| Jazz Pharmaceuticals INC. | $41.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.65 | 2019-2020 | |
| United Therapeutics Corporation | $36.36 | 2021-2023 | Tyvaso |
| Grifols USA, LLC | $30.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $27.91 | 2019 | |
| Resmed Corp | $24.28 | 2020 | |
| Advanced Respiratory, INC | $21.32 | 2020 | |
| Insmed, INC. | $19.44 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $19.41 | 2019 | |
| Daiichi Sankyo INC. | $18.59 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.46 | 2021 | |
| Genzyme Corporation | $18.02 | 2021 | |
| Masimo Corporation | $16.55 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.50 | 2019 | |
| Amgen INC. | $14.39 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.22 | 2021 | |
| Opko Pharmaceuticals, LLC | $13.32 | 2019 | |
| Vifor Pharma, INC. | $13.27 | 2019 | |
| Eisai INC. | $13.24 | 2021 | |
| Amarin Pharma, INC. | $13.00 | 2019 | |
| Veran Medical Technologies, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.